CONTENTS:
- The need for more nuance in headline adult cigarette smoking prevalence estimates [Editorial]. Hitchman S.C., Pearson J.L., Villanti A.C., p. 1327-1328.
- Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism? [Addiction debate]. Day E., Mitcheson L., p. 1329-1336.
- Pharmacotherapies as standalone treatments for addictions: why lessening won't work. Flynn P.M., p. 1337-1338.
- Patient-centred care and patient engagement to inform the use of psychosocial interventions with opioid substitution treatment: another path for Day & Mitcheson to follow. Strike C.J., Guta A., p. 1338-1339.
- Widening the perspective on opioid substitution treatment. Selin J., p. 1339-1340.
- Are UK opioid substitution treatment agencies fit for purpose? Raistrick D., p. 1340-1342.
- Response to commentaries: Neither optimism or nihilism... but reasons for hope. Day E., Mitcheson L., p. 1342-1344.
- Dimensional personality traits and alcohol treatment outcome: a systematic review and meta-analysis. Foulds J., Newton-Howes G., Guy N.H., Boden J.M., Mulder R.T., p. 1345-1357.
- Alcohol dependence and risk of somatic diseases and mortality: a cohort study in 19?002 men and women attending alcohol treatment. Holst C., Tolstrup J.S., Sorensen H.J., Becker U., p. 1358-1366.
- Commentary on Holst et al. (2017): The relationship between alcohol dependence and risk of somatic diseases and mortality - the black box strikes back. Bloomfield K., p. 1367-1368.
- Correlates of alcohol consumption on heavy drinking occasions of young risky drinkers: event versus personal characteristics. Dietze P., Agius P.A., Livingston M., Callinan S., Jenkinson R., Lim M.S.C., et al., p. 1369-1377.
- A National Swedish Longitudinal Twin-Sibling Study of alcohol use disorders among males. Long E.C., Lönn S.L., Sundquist J., Sundquist K., Kendler K.S., p. 1378-1385.
- Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study. Karriker-Jaffe K.J., Ji J., Sundquist J., Kendler K.S., Sundquist K., p. 1386-1394.
- A randomized controlled trial of brief interventions to reduce drug use among adults in a low-income urban emergency department: the HealthiER You study. Blow F.C., Walton M.A., Bohnert A.S.B., Ignacio R.V., Chermack S., Cunningham R.M., et al., p. 1395-1405.
- Commentary on Blow et al. (2017): Leveraging technology may boost the effectiveness and adoption of interventions for drug use in emergency departments. McCormack R.P., p. 1406-1407.
- Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Marsden J., Stillwell G., Jones H., Cooper A., Eastwood B., Farrell M., et al., p. 1408-1418.
- Commentary on Marsden et al. (2017): While epidemiological studies can help to identify areas of overdose risk, we need more focused hypothesis-driven trials to inform clinical intervention strategies. Kidd B., Matthews C., p. 1419-1420.
- Engagement in HIV care and its correlates among people who inject drugs in St Petersburg, Russian Federation and Kohtla-Järve, Estonia. Heimer R., Usacheva N., Barbour R., Niccolai L.M., Uusküla A., Levina O.S., p. 1421-1431.
- High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Bukten A., Stavseth M.R., Skurtveit S., Tverdal A., Strang J., Clausen T., p. 1432-1439.
- Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Murphy S.M., Polsky D., Lee J.D., Friedmann P.D., Kinlock T.W., Nunes E.V., et al., p. 1440-1450.
- Extended treatment for cigarette smoking cessation: a randomized control trial. Laude J.R., Bailey S.R., Crew E., Varady A., Lembke A., McFall D., et al., p. 1451-1459.
- Commentary on Laude et al. (2017): Extended treatment for cigarette smoking cessation. Hall S.M., p. 1460-1461.
- A randomized controlled trial of a brief intervention for alcohol and drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary health care in Chile. Poblete F., Barticevic N.A., Zuzulich M.S., Portilla R., Castillo-Carniglia A., Sapag J.C., et al., p. 1462-1469.
- Self-reported substance use in Iraq: findings from the Iraqi National Household Survey of Alcohol and Drug Use, 2014. Al-Hemiery N., Dabbagh R., Hashim M.T., Al-Hasnawi S., Abutiheen A., Abdulghani E.A., et al., p. 1470-1479.
- Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. McFall A.M., Solomon S.S., Lucas G.M., Celentano D.D., Srikrishnan A.K., Kumar M.S., et al., p. 1480-1487.
- Commentary on McFall et al. (2017): The need for harm reduction interventions that are effective for women who use drugs. Armstrong G., p. 1488-1489.
- Making visible the politics and ethics of alcohol policy research. Moore D., p. 1490-1494.
- Alcohol use from adolescence through early adulthood: an assessment of measurement invariance by age and gender. Fish J.N., Pollitt A.M., Schulenberg J.E., Russell S.T., p. 1495-1507.
- Alcohol marketing and youth drinking in Asia. Jiang H., Xiang X., Waleewong O., Room R., p. 1508-1509.
- Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. Osborne V., Serdarevic M., p. 1509-1510.
- Reply to Osborne & Serdarevic (2017): Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. Banerjee G., Edelman E.J., Barry D.T., Becker W.C., Cerda M., Crystal S., et al., p. 1510-1511.